MedTrace Logo

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

NCT07116746 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-05-15

No results posted yet for this study

Summary

This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.

Conditions

  • Gout
  • Gouty Arthritis
  • Hyperuricemia
  • Gout Chronic
  • Refractory Gout
  • Uncontrolled Gout
  • Tophaceous Gout

Interventions

DRUG

AR882 75 mg

Solid Oral Capsule

DRUG

XOI Low Dose

Solid Oral Tablet

DRUG

XOI High Dose

Solid Oral Tablet

Sponsors & Collaborators

  • Arthrosi Therapeutics

    lead INDUSTRY

Principal Investigators

  • Robert Keenan, MD · Arthrosi Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-03
Primary Completion
2026-11-30
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07116746 on ClinicalTrials.gov